Quantcast Fate Therapeutics Stock Quote | Stock Price for FATE | Financial News | myMotherLode.com

Financial News

Motherlode Stocks
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Fate Therapeutics (NQ: FATE)
14.14 USD  +0.37 (+2.69%)
Official Closing Price  /  Updated: 4:43 PM EDT, Oct 19, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 618,500
Open 13.82
Bid (Size) 12.51 (50)
Ask (Size) 16.24 (1)
Prev. Close 13.77
Today's Range 13.70 - 14.41
52wk Range 3.800 - 16.94
Shares Outstanding 52,858,446
Dividend Yield N/A
Performance
YTD
+124.44%
+124.44%
1 Month
+0.78%
+0.78%
3 Month
+30.08%
+30.08%
6 Month
+25.47%
+25.47%
1 Year
+238.28%
+238.28%
Top News
More News
Fate Therapeutics Appoints Wen Bo Wang, Ph.D. as Senior Vice President, Technical Operations
Fate Therapeutics, Inc. (NASDAQ: FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Wen Bo... Read More
from GlobeNewswire News Releases
Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced... Read More
from GlobeNewswire News Releases
More News
Read More
Fate Therapeutics to Present at Upcoming Investor Conferences
from GlobeNewswire News Releases
Fate Therapeutics Announces Pricing of Public Offering of Common Stock
from GlobeNewswire News Releases
Fate Therapeutics Announces Proposed Public Offering of Common Stock
from GlobeNewswire News Releases
Fate Therapeutics Announces Strategic Collaboration with ONO Pharmaceutical to Develop Off-the-Shelf, iPSC-derived CAR-T Cell Cancer Immunotherapies
from GlobeNewswire News Releases
Investors Snag FATE Even Cheaper Than Its Secondary Stock Offering
category Stocks
from Market News Video
Fate Therapeutics Enters into Exclusive License Agreement with Gladstone Institutes for CRISPR-based Cellular Reprogramming
from GlobeNewswire News Releases
Research Report Identifies Kronos Worldwide, The Gap, Citigroup, Cadence Design, SPX FLOW, and Fate Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
from GlobeNewswire News Releases
Top Buys by Directors: Redmile's $50M Bet on FATE
category Stocks
from Market News Video
First Week of May 2019 Options Trading For Fate Therapeutics (FATE)
category Stocks
from Market News Video
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Follow myMotherLode.com at these social networks Make Us Your Homepage Today Follow us on Facebook Follow us on Twitter Follow us on Youtube Follow us on LinkedIn Follow our RSS Feed
Yellow Pages

Popular Searches

Local Radio Stations
© Copyright 2000-2017 Clarke Broadcasting Corporation. All rights reserved.